Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TECH 
Bio-Techne Corp (TECH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: TECH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $66.23
1 Year Target Price $66.23
| 7 | Strong Buy |
| 3 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46.04% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.97B USD | Price to earnings Ratio 111.43 | 1Y Target Price 66.23 |
Price to earnings Ratio 111.43 | 1Y Target Price 66.23 | ||
Volume (30-day avg) 15 | Beta 1.47 | 52 Weeks Range 45.87 - 80.52 | Updated Date 09/13/2025 |
52 Weeks Range 45.87 - 80.52 | Updated Date 09/13/2025 | ||
Dividends yield (FY) 0.60% | Basic EPS (TTM) 0.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 6.02% | Operating Margin (TTM) 36.3% |
Management Effectiveness
Return on Assets (TTM) 6.3% | Return on Equity (TTM) 3.68% |
Valuation
Trailing PE 111.43 | Forward PE 25.97 | Enterprise Value 8558665524 | Price to Sales(TTM) 6.54 |
Enterprise Value 8558665524 | Price to Sales(TTM) 6.54 | ||
Enterprise Value to Revenue 7.02 | Enterprise Value to EBITDA 39.46 | Shares Outstanding 155550000 | Shares Floating 153704769 |
Shares Outstanding 155550000 | Shares Floating 153704769 | ||
Percent Insiders 1.1 | Percent Institutions 103.38 |
Upturn AI SWOT
Bio-Techne Corp
Company Overview
History and Background
Bio-Techne Corp was founded in 1981. Initially focused on developing and manufacturing hematology controls, the company expanded into cytokines and growth factors. Through strategic acquisitions and organic growth, Bio-Techne has become a leading provider of life science reagents, instruments, and services.
Core Business Areas
- Protein Sciences: Develops and manufactures recombinant proteins, antibodies, immunoassays, and related products used in protein research and diagnostics.
- Diagnostics and Genomics: Provides molecular controls, diagnostic assays, and related products and services, used in clinical diagnostics and genomics research.
- Cell and Gene Therapy: Offers specialized reagents, instruments, and services supporting the development and manufacturing of cell and gene therapies.
Leadership and Structure
Charles Kummeth is the President and CEO. The company has a Board of Directors that oversees corporate governance and strategic direction. Bio-Techne operates with a decentralized structure, with each business segment having its own leadership team.
Top Products and Market Share
Key Offerings
- Recombinant Proteins: High-quality proteins used in cell culture and research. Competitors include Thermo Fisher Scientific (TMO) and Merck KGaA (MKKGY). Market share data is not publicly available at a product level.
- ELISA Kits: Enzyme-linked immunosorbent assays for detecting and quantifying specific substances. Competitors include Thermo Fisher Scientific (TMO) and Abcam (ABCM). Market share data is not publicly available at a product level.
- Flow Cytometry Antibodies: Antibodies used in Flow Cytometry experiments. Competitors include Thermo Fisher Scientific (TMO), BD Biosciences (BDX). Market share data is not publicly available at a product level.
Market Dynamics
Industry Overview
The life science tools and reagents market is characterized by high growth driven by increasing research funding, advancements in genomics and proteomics, and the expanding biopharmaceutical industry.
Positioning
Bio-Techne holds a strong position in niche segments like protein sciences and cell and gene therapy, known for its high-quality products and strong brand recognition. The company's focus on innovation and strategic acquisitions strengthens its competitive advantage.
Total Addressable Market (TAM)
The total addressable market for life science tools and reagents is estimated to be hundreds of billions of dollars. Bio-Techne is positioned to capture a significant portion of this market, focusing on specialized and high-growth areas.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- High-quality products
- Focus on innovation
- Strategic acquisitions
- Diversified product portfolio
Weaknesses
- Reliance on research funding levels
- Integration risks from acquisitions
- Susceptibility to economic downturns
- Price competition in certain segments
Opportunities
- Expansion into emerging markets
- Increased demand for cell and gene therapy tools
- Growth in proteomics and genomics research
- Development of novel diagnostic assays
- Strategic partnerships and collaborations
Threats
- Competition from larger players
- Technological disruptions
- Changes in regulatory landscape
- Economic downturns affecting research funding
- Patent expirations
Competitors and Market Share
Key Competitors
- TMO
- DHR
- ABCB
Competitive Landscape
Bio-Techne competes with larger players like Thermo Fisher Scientific and Danaher. Bio-Techne differentiates itself through its focus on niche segments, high-quality products, and strong brand reputation.
Major Acquisitions
Asuragen
- Year: 2019
- Acquisition Price (USD millions): 320
- Strategic Rationale: Expanded Bio-Techne's molecular diagnostics portfolio and capabilities.
Growth Trajectory and Initiatives
Historical Growth: Bio-Techne has demonstrated strong historical growth driven by organic expansion and acquisitions.
Future Projections: Analysts project continued growth for Bio-Techne, driven by its strong market position and focus on high-growth segments.
Recent Initiatives: Recent initiatives include acquisitions to expand its product portfolio and investments in cell and gene therapy technologies.
Summary
Bio-Techne is a strong player in the life science tools market, driven by its high-quality products and strategic acquisitions. The company's focus on niche segments like cell and gene therapy provides significant growth opportunities. Potential threats include competition from larger players and fluctuations in research funding. Continued innovation and strategic investments are crucial for sustained success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Financial data is illustrative only and not reflective of the company's real data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bio-Techne Corp
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 1989-02-09 | CEO, President & Director Mr. Kim Kelderman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3100 | Website https://www.bio-techne.com |
Full time employees 3100 | Website https://www.bio-techne.com | ||
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.